Central retinal artery occlusion

Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing

Retrieved on: 
Monday, October 10, 2022
Other Manufacturing, Research, Genetics, Clinical Trials, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, Ignition, CA, Retina, Therapy, Retinal ganglion cell, Prevalence, Optogenetics, Retinal degeneration, Field line, Light, CGMP, Person, Biotechnology, Patient, B cell, Research, Program, Multimedia, Â, Severe cognitive impairment, Plasmid, Partnership, Retinitis, Visual acuity, Nyctalopia, Neuron, Ray, AAV, RP, CEO, RGC, DNA, Central retinal artery occlusion, HEK, Retinitis pigmentosa, Pharmaceutical industry, Vaccine, Hearth, Forge

View the full release here: https://www.businesswire.com/news/home/20221010005240/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221010005240/en/
    Forge will provide research-grade and GMP-Pathway plasmid manufacturing services, in addition to adeno-associated viral vector (AAV) process development, scale-up engineering, and cGMP manufacturing services for Ray Therapeutics program, RTx-015.
  • The program will continue to utilize Forges platform manufacturing processes, including its proprietary HEK 293 suspension Ignition Cells and pEMBR adenovirus helper plasmid.
  • All development and cGMP manufacturing activities will occur at the Hearth, Forges 200,000 square foot gene therapy cGMP production facility in Columbus, Ohio.
  • Ray Therapeutics lead candidate RTx-015 uses intravitreal administration, from which the vector diffuses into the retina and transduces primarily the RGCs.

Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

Retrieved on: 
Thursday, May 5, 2022
Vance DeGeneres, Central retinal artery occlusion, University, Vitamin A, Vital signs, Instagram, Twitter, U.S. Securities and Exchange Commission, Macular dystrophy, Association for Research in Vision and Ophthalmology, Stargardt disease, GLOBE, AES, Company, Safety, Food, Research, Eye, ARVO, Retinal degeneration, Adolescence, Patient, RBP4, Association, Macular degeneration, FDA, Qaf, DDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Severe cognitive impairment, Facebook, The Association, Ageing, Health, LinkedIn, Visual acuity, AMD, SAN, Lists of diseases, Pharmaceutical industry, Vaccine, Medical imaging, Public relations, Ophthalmology

This Phase 1b/2 study examined the safety and tolerability of LBS-008, a retinol binding protein 4 (RPB4) antagonist, in adolescent STGD1 subjects.

Key Points: 
  • This Phase 1b/2 study examined the safety and tolerability of LBS-008, a retinol binding protein 4 (RPB4) antagonist, in adolescent STGD1 subjects.
  • Preclinical studies have shown that RBP4 inhibition slows disease progression and prevents retinal degeneration in a STGD1 animal model.
  • Childhood-onset STGD1 is characterized by accumulation of bisretinoids which cause progressive retinal atrophy leading to rapid visual loss.
  • The Phase 1b/2 study is a multicenter, single arm, open-label study followed by a 2-year extension to evaluate safety, tolerability and efficacy of LBS-008.

Ray Therapeutics and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

Retrieved on: 
Tuesday, March 1, 2022
Other Manufacturing, Research, Genetics, Clinical Trials, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, Eye, The Hearth, Partnership, Optogenetics, Retinitis pigmentosa, RP, Ray, Nyctalopia, Prevalence, Retina, AAV, Ophthalmology, Therapy, CA, Neuron, Person, Central retinal artery occlusion, Multimedia, Biotechnology, Visual acuity, Retinal degeneration, Severe cognitive impairment, Patient, B cell, HEK 293, Light, Program, Field line, CGMP, Retinal ganglion cell, CEO, RGC, Medical imaging, Pharmaceutical industry, Forge, Hearth

View the full release here: https://www.businesswire.com/news/home/20220301005482/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220301005482/en/
    Forge will provide adeno-associated viral (AAV) process development, scale-up engineering and cGMP manufacturing services for Ray Therapeutics program, Ray-001.
  • All development and cGMP manufacturing activities will occur at The Hearth, Forges 200,000 ft2 gene therapy cGMP production facility in Columbus, Ohio.
  • We look forward to helping Ray Therapeutics advance their AAV manufacturing with an eye towards restoring vision in patients with ophthalmology disorders.
  • Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company.

Ray Therapeutics Closes $6M Seed Financing to Advance Novel Optogenetics Platform to Treat Blinding Diseases

Retrieved on: 
Tuesday, January 4, 2022
Science, Other Science, Research, Pharmaceutical, Optical, Health, FDA, Clinical Trials, Severe cognitive impairment, Therapy, Retina, Optogenetics, Retinitis pigmentosa, Retinal ganglion cell, Neuron, Field line, Patient, CA, Ophthalmology, Prevalence, CEO, Person, RGC, Partner (business rank), Nyctalopia, Retinal degeneration, Central retinal artery occlusion, Light, Visual acuity, B cell, Pharmaceutical industry, Medical imaging, RP, Retinitis Pigmentosa, Ray Therapeutics, RETINITIS PIGMENTOSA, RAY THERAPEUTICS

Ray Therapeutics , a biotech company developing optogenetic gene therapies for patients with blinding diseases, today announced the closing of a $6M seed financing round, led by 4BIO Capital.

Key Points: 
  • Ray Therapeutics , a biotech company developing optogenetic gene therapies for patients with blinding diseases, today announced the closing of a $6M seed financing round, led by 4BIO Capital.
  • Were excited to invest in Ray Therapeutics, which is developing a ground-breaking new approach to treat inherited retinal diseases using the power of optogenetics, Dmitry Kuzmin, Managing Partner, 4BIO Capital.
  • This seed financing round led by top-tier advanced therapies investor 4BIO Capital, enables us to advance our optogenetic gene therapy platform, pipeline and people, said Paul Bresge, CEO & Co-Founder, Ray Therapeutics.
  • Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases.

Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit

Retrieved on: 
Tuesday, October 19, 2021
ALS, IND, Visual impairment, Tissue, Death, PUFA, Cell damage, Investigational New Drug, Western world, FA, Reading, Oxidative stress, GLOBE, Patient, University, INAD, Animal, RT001, LA, Retinal pigment epithelium, Demonstration, GA, AMD, Infantile neuroaxonal dystrophy, Collection, Amyotrophic lateral sclerosis, Time, DHA, University of Pennsylvania, Vicious Circle, RATS, Disease, Drusen, LPO, Time-invariant system, Retina, Dihydroxy-E,Z,E-PUFA, Geographic atrophy, Inflammation, Central retinal artery occlusion, Degenerative disease, Dry, Injection, Â, Severe cognitive impairment, RPE, Lipid peroxidation, LOS, Program, Research, Stress (linguistics), PSP, Therapy, Vaccine, Pharmaceutical industry, Dietary supplement

LOS ALTOS, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that positive results from preclinical studies of RT011, the second compound to emerge from the company’s novel technology platform, are being reported in multiple oral presentations at the 2nd Annual Dry AMD Therapeutic Development Summit. Findings to be presented demonstrate that RT011, which is being developed as an oral therapy for the treatment of dry age-related macular degeneration (AMD), provided dose-dependent protection in animal models of oxidative damage implicated in dry AMD. Importantly, study results showed that animals treated with RT011 experienced preservation of retinal cells, photoreceptors, and visual function relative to control animals. The conference, which is being conducted in a virtual format, is being held October 19-21, 2021.

Key Points: 
  • Findings to be presented demonstrate that RT011, which is being developed as an oral therapy for the treatment of dry age-related macular degeneration (AMD), provided dose-dependent protection in animal models of oxidative damage implicated in dry AMD.
  • Importantly, study results showed that animals treated with RT011 experienced preservation of retinal cells, photoreceptors, and visual function relative to control animals.
  • The company expects to file an Investigational New Drug (IND) application for RT011 in the first half of 2022 and initiate first-in-human clinical studies in dry AMD soon thereafter.
  • Study results demonstrated that animals treated with RT011 experienced decreasing levels of retinal damage with increasing tissue concentrations of RT011.

Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy

Retrieved on: 
Wednesday, September 15, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Lineage Cell Therapeutics, OCT, Degenerative disease, Infection, Patient, Retinal pigment epithelium, Institute, Adult, Large-cell lung carcinoma, Visual acuity, Blood, Cohort, Geographic atrophy, Program, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Forward-looking statement, Antibody, Health, NYSE American, Bruch, U.S. Securities and Exchange Commission, Annual report, Severe cognitive impairment, Growth, Central retinal artery occlusion, Cancer, RPE, Drusen, Optical coherence tomography, Food, Therapy, Security (finance), Cell, Incidence, FDA, VAC2, Retina, TASE, Injury, HIV disease progression rates, Safety, Human, SEC, Method, European Medicines Agency, Autumn, Technology, Company, Multimedia, History, Compte rendu, AMD, Atrophy, Pharmaceutical industry, Medical imaging, Silviculture, Dentistry, Hospital

While competing efforts are focused on reducing the growth rate of geographic atrophy, Lineage has reported several patients whose areas of atrophy have stabilized or reduced in size.

Key Points: 
  • While competing efforts are focused on reducing the growth rate of geographic atrophy, Lineage has reported several patients whose areas of atrophy have stabilized or reduced in size.
  • Importantly, all three of the patients exhibiting restoration had confirmed historic growth rate in these areas and these data have been collected using multiple imaging modalities.
  • We are extremely pleased that our data is moving in a positive direction with each interim update we provide.
  • We will continue to collect follow up data and work towards a meeting with FDA to discuss key aspects of our program.